BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
4 reports, 1 independent
Updated Aug 10
Gone quiet
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioMarin Pharmaceutical stock received updates on July 18, 2026, including a price target boost from Citigroup, reported by Benzinga.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
BioMarin Pharmaceutical
American company
-
Benzinga
American news channel
-
Citigroup
American investment bank and financial services corporation
Related events
- Benzinga reported on the financial performance of UnitedHealth Group, while MarketBeat aggregated consensus ratings and target prices.
- Benzinga reported on the financial performance of Salesforce, Inc. on May 27, 2026.
- Benzinga is reporting on companies that are listed on the Nasdaq stock exchange.
- Benzinga reported on stock rating changes for Nvidia, while MarketBeat provided consensus rating data.
- MarketBeat aggregated analyst recommendations and price targets for BioMarin Pharmaceutical and Abeona Therapeutics Inc.